Assessing the Influence of ICER Reports on U.S. Payer Decision Making

The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute for Health and Care Excellence (NICE) assessments in the U.K., public reports on a product’s value are bound to influence discussions and negotiations between payers and manufacturers. However, the extent to which payers consider ICER assessments in their evaluation of therapies remains unclear.

To address this uncertainty, Trinity Life Sciences conducted a payer survey to better understand how U.S. payers really use ICER assessments. The goal was to shine a light on the impact ICER assessments and other third-party economic assessments truly have on the formulary decision making process and perceptions of price. In this advisory brief, we share key findings that emerged from our research to provide guidance for life sciences manufacturers.

Complete the form below to access the full advisory brief

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.